Mp28-01 Current Trends in the Management of Peyronie Disease, 2016-2021: Analysis of a Large Multi-Institutional Research Network

You have accessJournal of UrologySexual Function/Dysfunction: Peyronie's Disease (MP28)1 May 2024MP28-01 CURRENT TRENDS IN THE MANAGEMENT OF PEYRONIE DISEASE, 2016-2021: ANALYSIS OF A LARGE MULTI-INSTITUTIONAL RESEARCH NETWORK Saager T. Chawla, Sirpi Nackeeran, Marco-Jose Rivero, Samuel Sorkhi, Jaime A. Perez, Nannan Thirumavalavan, and Mahadevan Rajasekaran Saager T. ChawlaSaager T. Chawla , Sirpi NackeeranSirpi Nackeeran , Marco-Jose RiveroMarco-Jose Rivero , Samuel SorkhiSamuel Sorkhi , Jaime A. PerezJaime A. Perez , Nannan ThirumavalavanNannan Thirumavalavan , and Mahadevan RajasekaranMahadevan Rajasekaran View All Author Informationhttps://doi.org/10.1097/01.JU.0001008872.42208.7a.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Peyronie's disease (PD) is an acquired fibrotic disorder of the penis for which multiple interventions are available, including medical and surgical. In the present study, we evaluate PD prevalence and treatment nationwide trends from 2016 to 2021. METHODS: We queried TriNetX, a global federated research network, to identify males aged≥18 years diagnosed with PD by ICD-10 code between January 2016 and December 2021. The primary outcome was starting medication or undergoing a procedure after diagnosis. Medications analyzed included tadalafil, pentoxifylline, L-arginine, colchicine, and non-steroidal anti-inflammatory drugs (NSAIDs). Procedures analyzed included intralesional injection (CPT 54200), tunical plication (54360), plaque excision (54112), and penile prosthesis (54405). Treatment rates were analyzed by year (2016-2021) as well as by age bracket. RESULTS: A total of 34,601 adult males with PD were identified showing increasing prevalence trend (Figure 1A). The average age was 57.4±12.1 years. The most common procedure was intralesional injection (9.8% to 6.8%) followed by tunical plication (4.9% to 4.6%) and penile prosthesis (4.6% to 2.5%; Figure 1B). Pentoxifylline experienced a decrease in use (16.4% to 8.1%) throughout the observed period (Figure 1C). Pentoxifylline was used at lower rates with increasing age (15.7% in age70 years. Penile prosthesis is used at higher rates with increasing age (1.0% in age<40 years to 4.0% in age 70-79 years; Figure 1E). CONCLUSIONS: Pentoxifylline use is negatively correlated with age, likely due to patients resorting to surgical treatments as PD progresses. Intralesional injection is the most common procedure in all patients. Tunical plication is the most common procedure in those aged<40 years, suggesting the desire for more aggressive, definite treatment at younger ages. Penile prosthesis use is positively correlated with age, likely reflecting concomitant erectile dysfunction and the inconvenience of repeated injections at older ages. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e472 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Saager T. Chawla More articles by this author Sirpi Nackeeran More articles by this author Marco-Jose Rivero More articles by this author Samuel Sorkhi More articles by this author Jaime A. Perez More articles by this author Nannan Thirumavalavan More articles by this author Mahadevan Rajasekaran More articles by this author Expand All Advertisement PDF downloadLoading ...